Healthcare Global Enterprises Limited and Cvergenx, Inc. today announced an exclusive collaboration to develop, validate and launch Precision Genomic Radiation Therapy (PGRTTM) technology in India and Africa. 

HCG and Cvergenx shall form a joint venture which shall be the exclusive vehicle through which this technology will be made available in those countries.
The proprietary PGRTTM platform, developed at Cvergenx by Dr Javier Torres-Roca, co-founder and Director, Clinical Research, Department of Radiation Oncology, Moffitt Cancer Center & Research Institute, is the first clinically validated approach to guide radiation dosage based upon the Radio Sensitivity Index (RSI) of patients. 

The HCG/Cvergenx joint venture shall be the first initiative to validate and bring into clinical practice a solution that integrates genomics into radiation treatment planning and therapy in India, a company release said here on Thursday. "This pioneering technology will allow oncologists to precisely decide radiation treatment for cancer patients based on their genomic profile. It has the potential to truly revolutionize cancer care," said Dr B S Ajaikumar, Chairman and CEO of HCG. HCG headquartered in Bengaluru is the largest provider of cancer care in India.